Influence of age on combined effects of cyclosporin and nifedipine on rat alveolar bone

Journal of Periodontology

Volumn 75, Issue 2, 2004, Pages 268-272

  Spolidorio, Luís Carlos ^a   Spolidorio, D M ^a   Nassar, P O ^a   Nassar, C A ^a   Holzhausen, M ^a   Almeida, O P ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Alveolar bone; Animal studies; Cyclosporin A adverse effects; Nifedipine adverse effects

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CYCLOSPORIN A; EOSIN; HEMATOXYLIN; NIFEDIPINE;

AGING; ALKALINE PHOSPHATASE BLOOD LEVEL; ALVEOLAR BONE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; HISTOPATHOLOGY; MALE; MOLAR TOOTH; MONOTHERAPY; NONHUMAN; RAT; STATISTICAL ANALYSIS; STEREOLOGY; STEREOMETRY;

ADMINISTRATION, ORAL; AGING; ALKALINE PHOSPHATASE; ALVEOLAR PROCESS; ANIMALS; BONE DENSITY; BONE MARROW; CALCIUM; CALCIUM CHANNEL BLOCKERS; CYCLOSPORINE; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; NIFEDIPINE; RATS; RATS, WISTAR; TIME FACTORS;

EID: 1642307316     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2004.75.2.268     Document Type: Article

References (39)

1. Keown PA, Stiller CR. Cyclosporine: A double-edged sword. Hosp Prac 1987;22:207-215, 219-220.
2. Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993;45:953-1040.
3. Kovarik JM, Burtin P. Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opin Emerg Drugs 2003;8:47-62.
4. Seymour RA, Elles JS, Thomason JM. Risk factors for drug-induced gingival overgrowth. J Clin Periodontol 2000;27:217-223.
5. Fu E, Hsieh YD, Nieh S, Wikesjö UME, Liu D. Effects of cyclosporin A on alveolar bone: An experimental study in the rat. J Periodontol 1999;70:189-194.
6. Fu E, Hsieh YD, Mao TK, Shen EC. A histomorphological investigation of the effect of cyclosporin on trabecular bone of the rat mandibular condyle. Arch Oral Biol 2001;46:1105-1110.
7. McDonald JA, Dunstan CR, Dilworth P, et al. Bone loss after liver transplantation. Hepatology 1991;14:613-619.
8. Thomason JM, Seymour RA, Rice N. The prevalence and severity of cyclosporin and nifedipine-induced gingival overgrowth. J Clin Periodontol 1993;20:37-40.
9. de Mattos AM, Olyaei AJ, Bennett WM. Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis 1996;28:631-667.
10. Pesavento TE, Jones PA, Julian BA, Curtis JJ. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: Results of a prospective study. J Am Soc Nephrol 1996;7:831-835.
11. Guan D, Wang R, Lu J, Wang M, Xu C. Effects of nicardipine on blood cyclosporine levels in renal transplant patients. Transplant Proc 1996;28:1311-1312.
12. Duriez J, Flautre B, Blary MC, Hardouin P. Effects of the calcium channel blocker nifedipine on epiphyseal growth plate and bone turnover: A study in rabbits. Calcif Tissue Int 1993;52:120-124.
13. Ritchie CK, Maercklein PB, Fitzpatrick LA. Direct effect of calcium channel antagonists on osteoclast function: Alterations in bone resorption and intracellular calcium concentrations. Endocrinol 1994;135:996-1003.
14. Hefti AF, Eshenaur AE, Hassell TM, Stone C. Gingival overgrowth in cyclosporine A-treated multiple sclerosis patients. J Periodontol 1994;65:744-749.
15. King G, Fullinfaw R, Higgins TS, Walker RG, Francis DM, Wiesenfeld D. Gingival hyperplasia in renal allograft recipients receiving cyclosporin-A and calcium anatagonists. J Clin Periodontol 1993;20:286-293.
16. Thomason JM, Seymour RA, Ellis JS, et al. Determinants of gingival overgrowth severity in organ transplant patients. An examination of the role of HLA phenotype. J Clin Periodontol 1996;23:628-634.
17. Spratt H, Boomer S, Irwin CR, et al. Cyclosporin-associated gingival overgrowth in renal transplant recipients. Oral Dis 1999;5:27-31.
18. Katz I, Li M, Joffe I, et al. Influence of age on cyclosporin-A induced alterations in bone mineral metabolism in the rat "iN vivo." J Bone Miner Res 1994;9:59-67.
19. Wassef R, Cohen Z, Langer B. Pharmacokinetic profiles of cyclosporin in rats. Influence of route of administration and dosage. Transplantation 1985;40:489-493.
20. Morisaki I, Kato K, Loyola-Rodriguez JP, Nagata T, Ishuda H. Nifedipine-induced gingival overgrowth in the presence or absence of gingival inflammation in rats. J Periodont Res 1993;28:396-403.
21. Weibel ER. Selection of the best method in stereology. J Microsc 1974;100:261-269.
22. Kawana K, Takahashi M, Kushida K, Hoshino H, Sakata S, Inoue T. The effect of cyclosporin administration on bone metabolism in the rat evaluated by biochemical markers. J Endocrinol Invest 1996;19:499-504.
23. Buchinsky FJ, Ma Y, Mann GN, et al. Bone mineral metabolism in T lymphocyte-deficient and -replete strains of rat. J Bone Miner Res 1995;10:1556-1565.
24. Chowdhury MH, Shen V, Dempster DW. Effects of cyclosporine A on chick osteoclasts in vitro. Calcif Tissue Int 1991;49:275-279.
25. McCauley LK, Rosol TJ, Capen CC. Effects of cyclosporin A on rat osteoblasts (ROS 17/2.8 cells) in vitro. Calcif Tissue Int 1992;51:291-297.
26. Stewart PJ, Stern PH. Cyclosporines: Correlation of immunosuppressive activity and inhibition of bone resorption. Calcif Tissue Int 1989;45:222-226.
27. Fu E, Hsieh YD, Shen EC, Nieh S, Mao TK, Chiang CY. Cyclosporin-induced gingival overgrowth at the newly formed edentulous ridge in rats: A morphological and histometric evaluation. J Periodontol 2001;72:889-894.
28. Schlosberg M, Movsowitz C, Epstein S, Ismail F, Fallon MD, Thomas S. The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 1989;124:2179-2184.
29. Spolidorio LC, Spolidorio DM, Benatti C, Sampaio JE, Almeida OP. Combined effects of cyclosporin and nifedipine on gingival overgrowth in rats is not age dependent. J Periodont Res 2003;38:375-379.
30. Morisaki I, Fukui N, Fugimori Y, Murakami J, Daikoku H, Amano A. Effects of combined oral treatments with cyclosporin-A and nifedipine or diltiazem on drug-induced gingival overgrowth in rats. J Periodontol 2000;71:438-443.
31. Nishikawa S, Nagata T, Morisaki I, Oka T, Ishida H. Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. J Periodontol 1996;67:463-471.
32. Margiotta V, Pizzo I, Pizzo G, Barbaro A. Cyclosporin-A and nifedipine-induced gingival overgrowth in renal transplant patients: Correlations with periodontal and pharmacological parameters, and HLA-antigens. J Oral Pathol Med 1996;25:128-134.
33. Zimmermann B, Lange K, Merteris P, Bernimoulin JP. Inhibition of chondrogenesis and endochondral mineralization in vitro by different calcium channel blockers. Eur J Cell Biol 1994;63:114-121.
34. Redlich K, Pietschmann P, Stulc T, Peterlik M. Comparative study on the effect of calcium channel blockers on basal and parathyroid hormone-induced bone resorption in vitro. Pharmacol Toxicol 1997;80:262-265.
35. Klein L, Lemel MS, Wolfe MS, Shaffer J. Cyclosporin A does not affect the absolute rate of cortical bone resorption at the organ level in the growing rat. Calcif Tissue Int 1994;55:295-301.
36. Blair JT, Thomson AW, Whiting PH, Davidson RJ, Simpson JG. Toxicity of the immune suppressant cyclosporin A in the rat. J Pathol 1982;138:163-178.
37. Mason J. The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatric Nephrol 1990;4: 686-704.
38. Thomson AW, Whiting PH, Cameron ID, Lessels SE, Simpson JG. A toxicological study in rats receiving immunotherapeutic doses of cyclosporin A. Transplantation 1981;31:121-124.
39. Withold W, Friedrech W, Degenhardt S. Serum bone alkaline phosphatase is superior to plasma levels of bone matrix proteins for assesment of bone metabolism in patients receiving renal transplants. Clin Chim Acta 1997;261:105-115.